Jonathan Gertler

Founding Member

2023 - Current

Managing Director

2019

Managing Partner, CEO, and Co-Founder

2010

Back Bay Life Science Advisors (Back Bay or BBLSA) is a Life Science Sector strategic consulting and financial advisory firm. The senior leadership has extensive and broad reaching aggregate strategic and transactional experience, serving both large and emerging company needs for significant and sustainable growth.    Central to Back Bay’s value proposition is a holistic approach to meeting clients’ needs via multi-disciplinary and cross functional project management and deal execution.   We believe deeply that commercial assessment in the absence of expert scientific and clinical understanding misses key detail related to adoptive drivers and strategic growth challenges.  Similarly, extensive scientific or clinical acumen absent disciplined commercial analytics, experience and insights overlooks highly relevant data and can lead conclusions astray. Lastly, transactional decisions and considerations, whether internal investment or external acquisition, divestiture or sale, demands a rigorous analysis of inflection points and sensible valuation metrics; itself driven by the combination of technical and commercial acumen, as described above.   Back Bay’s model emphasizes leadership team presence, oversight and execution in all aspects of an assignment, leveraging the range of our collective insight and experiences.  Finding the right answer and then getting it done is where Back Bay excels.  Please visit – www.bblsa.com for more information or watch the Back Bay video. Securities transactions executed through Back Bay Life Science Advisory, LLC-Member SIPC/FINRA

Director

2000

Managing Director, Leerink Swann Strategic Advisors

2007 - 2010

Strategic Advisor in Life Sciences and Medical technology. Extensive clinical, transactional and strategic experience with large and emerging growth companies

Head, BioPharma Investment Banking

2007 - 2009

Managing Director

2001 - 2006

Led the Health Care investment Banking Group at AH for five years after previously running its Medtech Banking group. Led the group through significant growth in lead managed deals and M&A

Co-founder and President, Director

1998 - 2001

Endovascular Embolic Protection device company, invention by Roger D Kamm PhD and Jonathan P Gertler MD. Acquired by Embolic Protection inc. which was sequentially acquired by Boston Scientific

Associate Professor of Surgery, Harvard Medical School

1992 - 2001

Director of Vascular Surgery, Director of Vascular Labs, Assistant Professor

1988 - 1992

Instructor in Surgery

1986 - 1987

Instructor in Surgery

1986 - 1987

Instructor in Surgery

1986 - 1987